财联社10月30日讯（编辑 冯轶） 近日，港股生物医药明星个股信达生物(01801.HK)因深陷"资产贱 卖"舆论漩涡持续受到市场关注，公司股价也连续重挫。 截至10月30日收盘，信达生物连续3个交易日走低，累跌约20%，市值蒸发超过140亿港元。而这一切仅 仅是源于一桩约合1.6亿港元的收购交易。 公告发布后，这笔交易迅速引来市场和公司小股东的质疑。 一方面，由管理层收购上市公司资产本身就涉及关联交易，但信达生物甚至没有提前举行股东大会进行 商议，便直接公告。 另一方面，资料显示Fortvita作为信达生物推动国际业务的平台，承担着市场对公司业务出海的预期。 据了解Fortvita目前还持有信达生物研发管线中PD-1/IL2α融合蛋白IBI363的部分海外权益。9月4日， IBI363刚刚获得美国FDA授予快速通道资格。信达生物正在中国、美国、澳大利亚同时开展临床研究。 更令市场不解的是，本次收购标的资产Fortvita的估值采用的是净资产价格。这也意味着，本次交易中 收购方基本不需要支付任何溢价，从而也引发了市场关于"贱卖资产"的担忧。 面对市场的诸多质疑，信达生物在10月29日举行的"中信建投医药|信达 ...

SAN FRANCISCO and SUZHOU, China, Oct. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces the latest clinical results of a multicenter, open-label Phase 2 study (ClinicalTrials.gov, NCT05970978) of picankibart (R&D code: IBI112), a recombinant anti-inte ...

[Table_Main] 证券研究报告 | 公司首次覆盖 信达生物(01801.HK) 2024 年 10 月 24 日 | --- | --- | |------------------------------------------------------------------------------|------------------------| | 信达生物 买入（首次） | （ 1801.HK ） ：新时代 | | Pharma 所属行业：医疗保健业 / 药品及生物科技 当前价格 ( 港币 ) ： 45.00 元 | 代表，创新药全领域旗 | | | | | 证券分析师 | | | 周新明 | 舰 | 资格编号：S0120524060001 邮箱：zhouxm＠tebon.com.cn 李霁阳 资格编号：S0120523080003 邮箱：lijy7＠tebon.com.cn 投资要点 写在开篇：本篇为德邦医药团队关于信达生物的首次覆盖报告，公司在过去的几 年中已成为研产销一体的 biopharma，商业化成果斐然。站在当前时点，随着新一 代产品的不断获批及报产，公司有望即将迎来盈利拐点。 1 ...

证券研究报告 医药生物 首次覆盖报告 证券分析师 刘闯 S1350524030002 liuchuang@huayuanstock.com 市场表现： -24% -13% -2% 9% 20% 31% 23-1023-1123-1224-0124-0224-0324-0424-0524-0624-0824-0924-10 信达生物 恒生指数 相关研究 2024 年 10 月 20 日 信达生物 (1801.HK) 买入（首次覆盖） ——肿瘤与综合线双驱动，造就创新旗舰 Biopharma 投资要点： ➢ 国内旗舰 Biopharma，迈入创新收获期。信达生物成立于 2011 年，并于 2018 年在港交所 上市，专注研发肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物。目前公司已有 11 个产品获得批准上市，在研新药涵盖双靶 GLP1、PD-1/IL2 双抗等高潜力高价值管线，商业化 产品组合愈发丰富多元，营销产出及运营效率持续提升，已实现从 Biotech 到 Biopharma 的 成功转型。 ➢ 肿瘤：通过"IO+ADC"策略实现下一波全球肿瘤创新，巩固领先地位。1）已上市药物：信 迪利单抗(PD-1 ...

SAN FRANCISCO and SUZHOU, China, Oct. 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that primary endpoint of 12-week induction period was met in a multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study (ClinicalTrials.gov ...

Investment Rating - The report assigns a "Buy" rating for the company with a 6-month outlook [1] Core Viewpoints - The company's 2024 interim report met expectations with strong product sales growth and multi-sector breakthroughs [1] - Total revenue for 2024H1 reached 3.95 billion yuan, a 46.3% year-on-year increase [1] - Product revenue grew to 3.81 billion yuan, up 55.1% year-on-year [1] - The company demonstrated significant sales efficiency improvements with multiple quarters of high growth [1] Financial Performance - Gross margin improved to 84.1%, up 1.8 percentage points [1] - Sales and marketing expense ratio decreased to 48.6%, down 5.9 percentage points [1] - Management expense ratio reduced to 5.2%, down 4.9 percentage points [1] Pipeline Development - The company made significant progress in weight loss, oncology (ADC, next-gen IO), autoimmune, and ophthalmology fields [1] - Masdutide is expected to become the first domestic GLP-1 dual-target weight loss drug, with NDA submissions in 2024 [1] - IBI343 (CLDN18.2 ADC) and IBI363 (PD-1/IL-2α-bias) showed promising early data in oncology [1] - Picankibart (IL-23p19) is expected to submit NDA in H2 2024 for psoriasis treatment [1] - IBI311 (IGF-1R) is under NDA review, while IBI302 (VEGF/C) 8mg is in Phase III trials [1] Revenue Projections - 2024 revenue forecast increased from 7.225 billion yuan to 7.970 billion yuan [1] - 2025 revenue forecast raised from 9.193 billion yuan to 10.235 billion yuan [1] - 2026 revenue is projected to reach 13.143 billion yuan [1] Profit Projections - 2024 net loss forecast adjusted from -766 million yuan to -756 million yuan [1] - 2025 net profit forecast changed from -170 million yuan to 89 million yuan [1] - 2026 net profit is projected to be 1.003 billion yuan [1]

SAN FRANCISCO and SUZHOU, China, Oct. 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, and Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm, 002755.SZ), announced that the two parties have entered into a strategic collaboration regarding limertinib, a thi ...

Innovent 2024 INTERIM REPORT 中期報告 信達生物製藥 Innovent Biologics, Inc. (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限公司) Stock Code 股份代號:1801 | --- | --- | |------------------------------|-------| | 目錄 | | | 公司簡介 | 2 | | 公司資料 | 3 | | 財務摘要 | 5 | | 業務摘要 | 8 | | 管理層討論與分析 | 12 | | 其他資料 | 34 | | 簡明綜合財務報表審閱報告 | 57 | | 簡明綜合損益及其他全面收入表 | 58 | | 簡明綜合財務狀況表 | 59 | | 簡明綜合權益變動表 | 61 | | 簡明綜合現金流量表 | 62 | | 簡明綜合財務報表附註 | 64 | | 釋義 | 87 | 公司簡介 2 信達生物製藥 公司簡介概覽 信達生物製藥集團成立於2011年，以開發出老百姓用得起的 高質量生物藥為使命和目標，公司 ...

SAN FRANCISCO and SUZHOU, China, Sept. 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the New Drug Application (NDA) for picankibart injection, a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody, has been accepted by the Center f ...

SAN FRANCISCO and SUZHOU, China, Sept. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that clinical data of IBI363 (first-in-class PD1/IL-2α-bias bispecific antibody fusion protein) combined with bevacizumab in advanced colorectal cancer is present ...